Testing Cancer Patients Under 50 Only Missed 72% of Carriers

Jeff's Daily Pick. Doctors often offer inherited cancer gene tests only to patients under 50. In 39,184 patients, that rule would have missed 72% of those carrying a risky gene.

In the United States, researchers at Memorial Sloan Kettering Cancer Center tested every patient with a solid tumor for inherited cancer genes, whatever their age. The study, published in Cancer Discovery and announced by the American Association for Cancer Research on October 8, 2026, measured how much inherited risk a typical age based approach leaves undetected.

The test and the numbers

The team used the MSK IMPACT assay to look for germline pathogenic variants in 94 genes, using DNA from blood or saliva, in 39,184 patients. Overall, 16.3% carried at least one. Had testing been limited to patients under 50, the typical cutoff, 4,601 patients with pathogenic variants would have been excluded: 72% of all carriers.

The researchers also classified each cancer as early, average or late onset relative to the usual age for that cancer type, using one standard deviation from the mean. Pathogenic variants appeared in 18.4% of early onset, 15.6% of average onset and 12.3% of late onset cases. High penetrance variants, the ones most likely to cause disease, were found in 9.1%, 5.5% and 2.6% respectively.

Why relatives matter

A germline result does two jobs. It can change a patient's treatment, and it identifies relatives who may carry the same variant. Stadler, an author of the study, called cascade testing of relatives one of the most underused opportunities in cancer prevention, because once a variant is known, testing family members is targeted and informative, yet only a minority are tested. The cost of testing has fallen sharply; the data now argue that the age filter costs more in missed families than it saves. Our five minute guide covers how to read a cohort like this one.